Daniel Berger

Berger's arts-related publications include the books Militant Eroticism: The Art+Positive Archives of 2017, edited by Daniel S. Berger and John Neff and published by Sternberg Press (http://www.sternberg-press.com/?pageId=1802), and David Wojnarowicz: Flesh of My Flesh of 2018, from Iceberg Projects Press and distributed by SPD Books, Berkeley, CA (https://www.spdbooks.org/Products/9780692182963/david-wojnarowicz-flesh-of-my-flesh.aspx). For the 2016 exhibition Broken Flag, Iceberg Projects produced an accompanying chapbook of the same title by Daniel S Berger and curator Omar Kholeif.

In 2015, Berger acquired the archives of Art+Positive, an affinity group of ACT-UP NY. Later that year, Berger and John Neff (an artist, curator, and art educator who is a founding board member of Iceberg Projects) curated the first exhibition of the archives of Art+Positive, Militant Eroticism, at Iceberg Projects

In 2014, Dr. Berger founded the Daniel Berger Barbara DeGenevieve Scholarship in Photography, a yearly scholarship to an individual enrolled in the School of the Art Institute of Chicago's MFA program honoring the late Barbara DeGenevieve. A year later, Berger was listed by Newcity’s The Art 50 as one of the top 50 most influential individuals in Chicago's Art Community.

From 2012 to the present, Berger has been conducting studies with newer antiretroviral agents and participating in clinical trials that have led to a fine-tuning of treatment of HIV infection and contributed to the development of Gilead Sciences' Stribild, Complera, TAF (Tenofovir Alfonamide), Genvoya, Odefsey and GS 9883, as well as Merck's non-nucleoside reverse transcriptase inhibitor MK-1439 (Doravirine). Current studies include a study of African American HIV patients (GS-US-380-4580) with the protocol title, "A Phase 3b, Multicenter, Open-Label Study to Evaluate Switching From a Regimen of Two Nucleos(t)ide Reverse Transcriptase Inhibitors (NRTI) plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically- Suppressed, HIV-1 Infected African American Participants."

In addition to his medical and research practices, Berger is an avid collector of contemporary art, with a specialization in works by African-American, Chicago-based and queer artists. In 2010, he opened Iceberg Projects, a not-for-profit art gallery, in a refurbished carriage house behind his home in Chicago’s Rogers Park neighborhood. Iceberg Projects is operated by Berger and a board of arts professionals including Huey Copeland, Doug Ishcar, John Neff, Carrie Schneider, and Rebecca Walz. A Chicago Reader profile of Berger discussing his collection and work with Iceberg Projects is available at http://www.chicagoreader.com/Bleader/archives/2012/10/10/daniel-berger-quietly-redefining-what-it-means-to-support-the-arts.

Since 2012, Berger has been a member of the Board of Governors for the School of the Art Institute of Chicago. In 2016, he joined the Collections Committee of the Museum of Contemporary Art, Chicago. He is also Co-President of the Board of Trustees for the Leslie-Lohman Museum, New York, where he has been a trustee and Collections Committee member since 2016.

Berger has received numerous awards for his work as a researcher and teacher, including the Charles E. Clifton Leadership Award "For excellence and leadership to the Chicago HIV community" (2006), the Distinguished Researcher in HIV Medicine Award from Serono Laboratories (2000) and the American College of Physicians’ Preceptor Award for outstanding teaching in internal medicine (1996).

During the years 2005-2010, antiretroviral therapy for HIV disease experienced a revolution in therapeutics. Berger was heavily involved as principal investigator of these agents and co-authored several resultant iconic publications of trials including the Power 2, Titan, Duet and Startmrk studies and the first studies of elvitegravir. Berger often lectures to physicians around the US on topics relating to incorporating of newer antiretroviral therapies into treatment. Additionally, Berger frequently publishes editorial articles in the lay press.

During the first years of HIV treatment development, Berger presented his work on several watershed studies on the development of the drug cocktail. Highlights include a presentation at the 1992 International AIDS Conference describing the first use of combination therapy with zidovudine and didanosine for patients who were consistently p24 anti-genemic despite zidovudine monotherapy. Also, Berger conducted the first investigations of interleukin II in advanced HIV disease patients, presented at the 1998 International Conference on AIDS.

Daniel Berger (born November 25, 1957) is a leading HIV specialist in the United States. A Clinical Associate Professor at the Chicago campus of the University of Illinois College of Medicine, Berger is also founder and medical director of Northstar Medical Center, Chicago’s largest private HIV/AIDS research and treatment center.

Born in Brooklyn, New York, Daniel Berger is the son of Hungarian immigrants Kathy and Kalman Berger and brother to Kenneth Ira Berger. Kathy Berger (1926-2016) was a survivor of Nazi Concentration camp Auschwitz, liberated from Bergen-Belsen at the end of WW II. Her biography and testimony has been recorded and documented in the Shoah Foundation archives (http://vhaonline.usc.edu/viewingPage.aspx?testimonyID=10290&returnIndex=0USC). Kalman Berger (1921 - 1984) was a survivor of Nazi slave labor in Hungary, Poland, Germany, and Russia. Berger's brother Kenneth Ira Berger is a Professor (Departments of Medicine and Neuroscience / Physiology) and Medical Director at the Tisch Pulmonary Function Lab at NYU. Has conducted extensive research and has more than 50 publications in the areas of pulmonary physiology, cardiovascular and pulmonary outcomes of World Trade Center exposure, mucopolysaccharidosis, Pompe's Disease and pulmonary manifestations of obesity (http://www.med.nyu.edu/biosketch/bergek01).